Bank Of America Corp Vaxxinity, Inc. Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.62 - $0.86 $165,090 - $228,996	-266,275 Reduced 74.33%	91,981 $66,000
Q4 2023 Feb 14, 2024	SELL	$0.7 - $1.31 $78,961 - $147,770	-112,802 Reduced 23.95%	358,256 $304,000
Q2 2023 Aug 14, 2023	BUY	$1.73 - $2.79 $275,879 - $444,915	159,468 Added 51.18%	471,058 $1.19 Million
Q1 2023 May 12, 2023	SELL	$1.43 - $4.24 $344,391 - $1.02 Million	-240,833 Reduced 43.6%	311,590 $707,000
Q4 2022 Feb 10, 2023	SELL	$1.31 - $2.62 $3.47 Million - $6.95 Million	-2,650,797 Reduced 82.75%	552,423 $773,000
Q3 2022 Nov 14, 2022	SELL	$1.64 - $2.48 $20,780 - $31,424	-12,671 Reduced 0.39%	3,203,220 $6.34 Million
Q2 2022 Aug 12, 2022	BUY	$1.55 - $6.95 $4.96 Million - $22.2 Million	3,200,033 Added 20179.3%	3,215,891 $5.05 Million
Q1 2022 May 16, 2022	BUY	$3.7 - $8.6 $57,934 - $134,658	15,658 Added 7829.0%	15,858 $68,000
Q4 2021 Feb 08, 2022	BUY	$5.55 - $18.46 $1,110 - $3,692	200 New	200 $1,000

469K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Market Cap $1.12M
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.